New hope for bladder cancer patients unresponsive to standard therapy
Disease control
AVAILABLE
This program provides access to an experimental treatment called cretostimogene for people with a type of bladder cancer that has not responded to standard BCG therapy. It is for patients with non-muscle invasive bladder cancer, specifically carcinoma in situ with or without high…
Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC